Share Name Share Symbol Market Type Share ISIN Share Description
Integumen Plc LSE:SKIN London Ordinary Share GB00BYWJ6269 ORD 0.01P
  Price Change % Change Share Price Shares Traded Last Trade
  -0.03 -1.50% 1.97 6,564,199 14:33:41
Bid Price Offer Price High Price Low Price Open Price
1.96 1.98 1.99 1.95 1.99
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
  0.27 -2.12 1.00 2.0 19.0
Last Trade Time Trade Type Trade Size Trade Price Currency
16:23:01 O 176,832 1.97 GBX

Integumen (SKIN) Latest News

More Integumen News
Integumen Takeover Rumours

Integumen (SKIN) Share Charts

1 Year Integumen Chart

1 Year Integumen Chart

1 Month Integumen Chart

1 Month Integumen Chart

Intraday Integumen Chart

Intraday Integumen Chart

Integumen (SKIN) Discussions and Chat

Integumen Forums and Chat

Date Time Title Posts
16/7/201915:26Integumen - Skin in the Game5,290
26/2/201914:05True Judaism a means to a co-existance with Non-Jews9
06/4/201711:44Skin in the Game2

Add a New Thread

Integumen (SKIN) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2019-07-16 15:23:021.97176,8323,476.34O
2019-07-16 15:22:301.97196,7533,867.97O
2019-07-16 15:19:411.96250,0004,900.25O
2019-07-16 15:18:181.97375,0007,368.75O
2019-07-16 15:13:561.97200,0003,930.00O
View all Integumen trades in real-time

Integumen (SKIN) Top Chat Posts

Integumen Daily Update: Integumen Plc is listed in the sector of the London Stock Exchange with ticker SKIN. The last closing price for Integumen was 2p.
Integumen Plc has a 4 week average price of 1.86p and a 12 week average price of 1.27p.
The 1 year high share price is 2.61p while the 1 year low share price is currently 0.35p.
There are currently 977,183,330 shares in issue and the average daily traded volume is 14,694,426 shares. The market capitalisation of Integumen Plc is £19,250,511.60.
tickboo: Just looked in again. I will agree that proof is in the pudding re figures but also where it's headed. I believe since Aug this has been a great turnaround. Clearly from a very low base but getting rid of underperforming assets so reducing the cost base as well as changing the business model to generate more money from each client albeit less volume seems a good move. H1 looks good and yes they'll need to continue the trajectory so H2 needs to be £1m+ so FY will be £1.5m+ meaning they'll be loss making but not massively and will still have cash on the balance sheet and if H1 2020 is better than H2 19 I doubt they'll need to raise any cash for working capital. The Rinocloud margins are even better and they'll probably need additional physical lab space assuming demand continues comes H2.The big game changer will be deals with CROs/trial cos as SKIN won't need to increase costs to facilitate that kind of rapid growth. Those deals take a longer time to negotiate by hopefully come H1 2020 we'll have one in place.Let's see but I take the point that no amount of pumping on BBs will will sustain a price/market cap increase. That said, I think it's positive the CEO looks in on here to check sentiment and sometimes post if falsehoods are being spread (like a raise to keep the lights on). I look forward to the AGM and the presentation. The CEO and Sales Director have a lot of skin in the game and they'll only benefit from a sustained higher share price andnfoven they only get paid some £120k and the CEO in shares they are closely aligned.
tickboo: Lemming investors blog -Integumen strengthens senior sales and IT executive teamLabskin AI opens digital hub in Ireland to accommodate expansion plan across the EU and USIntegumen announces the appointment of Paul Ryan as Head of Enterprise Sales at Labskin AI. Paul has managed strategic partnering programmes and initiatives with companies such as Siemens, Microsoft, Accenture and IBM and joins the Company from 8 West Consulting, a company with more than 240 personnel, where he was Head of New Business Development. He has worked with a network of clients that include Avon, Image Skincare, Estee Lauder and Anthem Inc., a Fortune 50 US health insurer. The Company also announces the appointment of Colin O'Sullivan as Chief Information Officer (CIO). Colin is a 20-year veteran and joins the team from the Australian Medical Association where he was Group Information Officer. He brings extensive cross-platform software experience in medical and science applications ranging from enterprise applications, cloud computing, artificial intelligence, IT operations, customer experience and development operations. Over a six-year period, Colin was responsible for transforming the online business of the Australian Medical Association.Make no mistake, these appointments speak volumes as to the credibility of SKIN as a company, technology, markets, etc. These appointments should offer encouragement to investors and demonstrate the direction the company is heading. I asked CEO. Gerard Brandon about incentivising such high calibre management and aligning this with investors. In typical fashion, a straightforward no-nonsense response; "They are paid salary plus strong results orientated bonus. I am a strong believer in removing external concerns from to people so they focus on what they do best. Deliver results. If they hit their target everyone wins, big time as their share option package rises with everyone else." "The great positive on exercising of warrants are that they are cheap to access to extra working capital. No advisor fees and everyone wins when supportive shareholders can exercise "in the money" warrants. Of course, the massive liquidity in the Share means even if they were sold they would disappear in an hour of trading. So if you look back at the warrants exercised since the RinoCloud acquisition, warrant income more than covers 9 months salary if both appointees and by the time that comes around the increase in sales will address the rest. Plus hitting the targets means more sales, higher share price and these executives are well rewarded, as are Shareholders. If there are Warrants exercised "in the money" the company is doing the right things all around."Labskin AI Digital Hub IrelandFollowing the RinoCloud acquisition and integration of data management and analytic services into Labskin AI, Integumen has taken new offices in Cork, Ireland to centralise global IT operations for the Group. These state-of-the-art facilities will manage IT and further AI development, incorporating Labskin AI, the virtual laboratory-as-a-service that complements the Labskin laboratory services in York, UK and provides online customer support to clients around the world.Gerard Brandon CEO of Integumen commented:"We are delighted and fortunate to add these two exceptional individuals to the Integumen team. Under Paul's guidance, the sales team will advance the growth of Labskin AI by leveraging the existing sales, marketing and distribution channels of the Labskin laboratory services. Colin's Australian continent AI and IT operational expertise ensures Labskin AI has an architect capable of building out continent-wide bases to deliver a robust global infrastructure.Our new offices in Cork, Ireland, bring the core digital and enterprise sales teams together and are located close to many US and EU pharmaceutical corporations that fit our client target profiles. This expansion adds another exciting new chapter for Integumen."
pwhite73: TraderBus Don't make excuses for this falling share price. SKIN is not a mature company that has plateaued. If the CEO is to be believed it is at the cutting edge of a new revolution in skin care and other non-animal testing clinical applications. SKIN should be going up in a straight line not heading back to any previous placing prices.
pwhite73: Katsy No it doesn't wash with me. There has been sustained buying for the last hour and the price has just moved down again. There is a seller in the background I suspect its Venn. Now what should happen at some point is that Turner Pope say right you've sold enough for today and turn their tap off. That's how the orderly market works. Future retail investor buys lead to a rise in the share price. Venn are happy and retail investors are happy. That's how it should work until the share price has risen and Turner Pope lets Venn in again at a higher value. But to allow a constant drip drip of the share price all the way back to 1.4p is wrong.
under the radar: Gerard J Brandon @gjbrandon Well it is out now. #SKIN share price put pressure to release news that offers a unique solution to medical device and clinical trials companies that have been stuck in the old testing methods for decades
under the radar: Investor evening - May 13thToday 07:08Nice to wake up to this - 'If you want to find out how, in less than 9 months, new management have: · Cleared over £2m of short and long-term debts beginning with a cash deficit and no credit; · Eliminated multiple outstanding litigation disputes saving £495,000; · Increased revenues by 350% in the last 4 months of 2018; · Bought a company in April 2019 for £3m with growing revenues; · Placed £2.5m at 300% higher than the lowest share price, since taking over; · Turned a £1.5m market cap, close to bankruptcy, into a £15m market cap company; and, · Increased shareholder value by more than 400% from the lowest share price since taking over'
dynam1te: 12:15 13 Mar 2019 Integumen’s Labskin technology has been used by some of the biggest names in pharma for years, but a small tweak in how it is sold has led to a surge in sales since new boss Gerry Brandon came in Gerry Brandon has been a busy man since taking over the reins at Integumen PLC (LON:SKIN) last August. He took the job after speaking to the company’s chairman, Tony Richardson, who he grew up with in Dublin back in the 1970s. The pair would go on to work with each other at wound care specialist Alltracell Pharmaceutical, which they floated on AIM just after the turn of the millennium. Before his arrival, Integumen had been burning through the funds and debt they had secured, faster than their ability to cover costs, without much to show for it. “There were seven board members and eight members of staff when I took over,” says Brandon. “It was far from an integrated group of four companies and management had simply overlooked, or perhaps misunderstood what it was that they actually had.” What they couldn’t see was Labskin, a laboratory-grown skin that is used by cosmetics and pharmaceutical companies to see how their latest products will react to human skin. The 'Rolls-Royce of lab-grown skin' It was this piece of technology that convinced Brandon to take the top job at Integumen. “Labskin is the Rolls-Royce of laboratory-grown skin for testing, but they were selling it for the price of a Mini Cooper,” he explains to Proactive. “Every other laboratory-grown skin testing product operates in a sterile environment: In other words, you put the product on to a sterile skin. “With Labskin, we can grow bacteria on it, so we can create models for acne, eczema, psoriasis and so on. It has even been tested on Ebola.” In short, Labskin gives scientists a much better idea of how their cream or gel or make-up will react in the real world. Not only does it make animal testing redundant, the added accuracy it gives researchers reduces R&D costs by helping to improve success rates when the product is eventually taken through to Phase II clinical trials. But before he could start to make the most out of Labskin, he needed to slim the business down. Brandon ditched the loss-making oral health brand, TSpro, as well as Integumen’s Visible Youth anti-ageing products. He also trimmed the number of board members from seven to four. Now a marketing tool for cosmetic giants With the company restructured, Brandon was able to focus on growing the sales of Labskin, which were relatively small even though some of the world’s biggest companies had been using it for years. “The old management were selling it into laboratories with a restricted R&D spend,” Brandon explains. Realising the potential for Labskin to be used as a stamp of quality, he started to approach companies’ marketing decisionmakers – the ones within a business who always have more money to spend. “It was just a matter of selling it into a completely different department of the same company. “Instead of selling that proposition into companies as a test for sensitivity or allergens, we now offer the marketing department an opportunity to say, ‘our product can give you this benefit or that benefit’.̶1; As a result, clients who used to pay £2,000 for a simple test are now paying upwards of £50,000 to qualify claims about the impact of their product as an anti-ageing solution or balancing the skin’s good and bacteria. That had an immediate effect on Integumen’s top-line: Labskin revenues totalled £149,000 in the first six months of 2018, but that figure surged by almost 350% in the second half of the year. AI is the future of Labskin Brandon isn’t standing still, either. With the help of artificial intelligence firm Rinocloud, he and his team are building Labskin-on-a-chip, which will record every treatment tested on the Labskin platform and store its effects in a database. That will give every dermatology clinic with a computer, the ability to take a swab of a patient’s own skin bacteria, place it on the Labskin, run it against the database, and advise what the best course of treatment might be. Then there’s Labskin AI, a digital extension to the lab-grown skin which Brandon likens to the life science equivalent of Airbnb. It offers remote contract rental of laboratory equipment from service providers to buyers of those clinical test services, much like Airbnb matches holidaymakers with accommodation, without ever owning the house or apartment. Brandon says the combination of Labskin-on-a-chip and Labskin AI should take Integumen to the next level as it is a combination of scaling as a software rather than a physical operation only, and he is targeting 150 companies with revenue in excess of £500mln. That might sound ambitious, but Brandon reckons is far from impossible. “There are 3,685 companies that are large enough in the world to fit within that category. So, 150 is more than achievable.” The near-500% rise in the share price since his arrival would suggest that the market shares his optimism for the future.
buywell2: On this expeditious occasion I would like to bring to my admiring fans attention ,another share what I like LIDCO (LID) I have recently created a thread on it and just like SKIN its share price is/was bombed out but is JUST starting to perk up News Flow there has just turned positive following the exit of a distressed institutional seller City Financial who has just been in the news regarding calling in the administrator. Two great RNS's in a week and like SKIN ... is very likely to be acquired at the current share price by Edwards Lifesciences . I jest not GLA
sja123: Profiting when markets get it wrong Published on July 17, 2018 Gerard Brandon Gerard BrandonFollow Chief Executive |Author|Speaker|Investor Like4 Comment2 2 As CEO designate of Integumen Plc (LON: SKIN), I write this in my personal capacity before taking up my new position as CEO of Integumen in August. All investing is hard, because the public markets can be a great humiliator. Market conditions, overall valuations levels, capital availability, exit conditions, all these things are outside the control of all companies, not least early commercial stage. The continued pace of innovation and the opportunity to build great companies, off of the back of great technologies, either new, wrongly positioned or badly managed is how I have built companies in the past. So when markets drive a stock/share price lower, rather than have me running to an exit, I become fixated on the underlying technologies to see what is missing, or being missed. Something is wrong, but not always everything is wrong. No single person, or even a small team, can be good at everything and so the key to building a great business is to be focused on what you are good at. My expertise is combining great technology advances and integrating them into viable commercial business opportunities. Focus has a real cost. There are deals I have seen that have absolutely great potential, but I have had to just say no, or sell them off to allow them to flourish elsewhere. On the other hand, Cellulac has been a 6-year project for me, so far. Now, with a large minority shareholding, joining the Board, and taking up the CEO position of Integumen means it is part of that bigger integrated journey with Cellulac. How is it possible to build a range of skin, wound care and cosmetics for £2m? The rationale for me was that it is not financially possible to build a range of cosmetic, wound care and skin care products that are ready and on the market for £2m. It would also take 5 years, at least. In fact, when I was building Altracel 25 years ago it took a total of £22m and 6 years to get to commercial scale. That went well and the outcome was a global distribution sales channel for the same type of products that are in Integumen. When the opportunity came to get access to a range of similar products on the market it was a no-brainer. On top of that it comes with the ability to roll in the Cellulac bioplastic ingredients and natural oils into the cosmetic, skin and wound care products of Integumen. The big loss you see in the Integumen accounts published yesterday relates to intangible assets and goodwill. This was just a paper loss. A cleansing, so to speak, before myself and my operations management who previously grew Alltracel, integrate the Cellulac products and technology into Integumen. Back in 1996, my first public company, Alltracel, was started from nothing. Sales of wound care, skin care and cosmetic products for shaving grew from zero to £33m from 2002 to 2006 with EBITDA of over £2.5m by the time it was sold 10 years ago to Hemcon for $55m in debt and cash. To invest well you need a big picture view, a proactive approach, not reactive. The entrepreneur is the hero of any company. They are all in. There is no diversification. I put almost 30% of my own personal shares of Cellulac, that was built over the last 6 years, into Integumen. I subscribed for £50,000 of my personal money in the subscription shares of Integumen. Two other directors, each put in £10,000. Two investors in Cellulac also participated for £250,000. So my skin (pun intended) and other Cellulac investors are totally committed, like bacon at breakfast. The next phase of integration, on the public markets, will be fun and the bigger picture end game is well advanced. PhD is not scientific, it stands for Pig Headed Determination. Gerard Brandon is CEO designate of Integumen PLC. He is also CEO of Cellulac PLC, a biodegradable plastic ingredient and Omega 3 from microalgae producer, and a serial pharma and biochemical engineering entrepreneur. A finalist in Ernst & Young Entrepreneur of the Year and Fellow of Ryan Academy of Entrepreneurs, Ireland. He was co-founder and CEO of Alltracel Pharmaceuticals plc, which completed an IPO in 2001 and was sold in 2008 for a value of $55m to Hemcon Inc., USA.
74tom: Thanks for updating the summary Mulligut. I’m looking forward to the next trading update where hopefully we will get a split of the revenues by business unit. Re-reading the 27/9 RNS, the trading update for Labskin really stands out. “Since the half year end, sales for Labskin services have accelerated to a monthly run rate above the entire revenue of Labskin for the first six-months of 2018, which was £49,000.”; My stab at putting more detail on the estimated 2018 revenues; Labskin: If Labskin revenues were £49k+ per month and accelerating at the end of September, full 2018 revenues could look like; H1 - £49k - actual Q3 - £94k - Sep (£49k), Aug (£30k), Jul (£15k) Q4 - £150k - based on September run rate, leaving potential upside 2018 Total - £293k TSPro H1 revenues were £95k, however the August interims mentioned divestment was likely due to the high marketing cost required H2 estimate - £20k H2 could obviously be higher or lower, but wouldn’t expect it to drop to 0 straight away... Stoer Skincare We can calculate that H1 revenues couldn’t have exceeded £5k, so were tiny. However, Thursdays RNS is intriguing as it states Stoer is the main reason for the outperformance vs 2017... Impossible to say what this means from a revenue point of view for Stoer, but for the purpose of this exercise let’s assume a prudent £50k, but this could be significantly higher. Cellulac Then we have 50% of Cellulacs revenues to account for from 1st November. Unfortunately, the 2017 accounts filed at Companies House have redacted the turnover line. We do know that profit after exceptional items was £419k, so I’d estimate revenues of circa £1m but could be higher or lower than this... Assuming £1m for 2018, 2 months of revenues share would equate to £83k for SKIN. Visible Youth - another business to be divested, assume 0 revenues here. 2018 Revenue Summary Labskin : £293k TSPro : £115k Stoer Skincare : £55k Cellulac : £83k Total £546k H1 : £149k actual H2 : £397k estimate Of course costs are arguably more important, and we don’t have any guidance here. H1 EBITDA loss was £744k on revenues of £149k. If H2 costs remained the same (£744k + £149k = £893k) and revenue was £397k as my working above, EBITDA loss would be £496k. However, we know marketing costs for Stoer have been reduced whilst Visible Youth & TSPro have been sidelined, so in theory costs could be significantly lower than H1. If any of these estimates seem wildly out, feel free to correct them. Things are really looking up here in my opinion, another good trading update + the resolution of Nicholson/Meruriali issue, should result in the Share Price beginning to reflect the growth occurring in the business & the exciting future ahead...
Integumen share price data is direct from the London Stock Exchange
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20190717 04:56:56